Re:meat today announces its strategic rebrand to Curve, reflecting the company’s expanded mission and technology platform aimed at enabling scalable, cost eGicient biomanufacturing of proteins across industries.
While the potential of biomanufacturing is widely recognised, scale has remained the limiting factor. Curve addresses this challenge by developing modular, intelligent production systems that close the gap between basic food-grade fermenters and costly pharma-grade setups. This unlocks commercially viable production of proteins at an industrial scale — in food, health, materials, cosmetics and more.
“Scaling biotech is the next industrial revolution — but it demands tools built for this century, not the last,” says Jacob Schaldemose Peterson, Co-founder & CEO of Curve. “With Curve, our ambition is to unlock scalable biomanufacturing — at cost points that finally make industrial deployment possible.”
The demand for aGordable, safe and sustainable proteins is accelerating — and it reaches far beyond food. Proteins are the foundation of future nutrition, healthcare, materials, animal feed and more. But today’s production systems were never built for these new markets. They are resource-heavy, slow to scale and economically misaligned. To unlock the next era of biotech, we need technology that can produce complex proteins at an industrial scale, with minimal cost and environmental impact. Smarter biomanufacturing is how we enable healthier living, greener industries — and a more resilient future.
Curve’s core platform, BIOBRIC, is engineered for cost leadership. The system is designed to reduce CapEx by up to 70%, accelerate process optimisation, and enable commercially viable precision fermentation and cultivated meat.
“Cost-eGicient cultivated meat production has always been the ambition for Re:meat”, says Torbjörn Sahlén, investor and board member at Curve. “However, experience shows that if we focus exclusively on that, we are not maximising our ability to scale and leave significant potential untapped. This shift — and consequently the name change to Curve — reflects this strategic opportunity.”
Curve works closely with precision fermentation and advanced biotech companies to run joint scale-up trials, optimising strains, media and processes before licensing validated systems to industrial producers. The rebrand marks both a strategic and technology milestone: moving from a single vertical into a protein platform powering the industries shaping tomorrow.
About Curve
Curve is a biotechnology company based in Sweden developing next-generation, modular bioreactor systems to scale production of proteins through precision fermentation and cell cultivation. By integrating hardware, simulations and real-time process learning, Curve enables eGicient, commercially viable biomanufacturing for emerging industrial biotech markets.
For media inquiries:
jacob@curvebio.tech www.curvebio.tech
%20Large.jpeg)
